Theranostic Applications of Lutetium-177 in Radionuclide Therapy

Title:Theranostic Applications of Lutetium-177 in Radionuclide Therapy

Volume: 9 Issue: 1

Author(s): Tapas Das and Sharmila Banerjee

Affiliation:

Keywords: ¹⁷⁷Lu, Theranostic applications, Metastatic bone pain palliation, Peptide receptor radionuclide therapy, Pharmacokinetic mapping.

Abstract: Lutetium-177 has been widely discussed as a radioisotope of choice for targeted radionuclide therapy. The simultaneous emission of imageable gamma photons [208 keV (11%) and 113 keV (6.4%)] along with particulate β^- emission [β_(max) = 497 keV] makes it a theranostically desirable radioisotope. In the present article, the possibility of using two ¹⁷⁷Lu-based agents viz. ¹⁷⁷Lu-EDTMP and ¹⁷⁷Lu-DOTATATE for theranostic applications in metastatic bone pain palliation (MBPP) and peptide receptor radionuclide therapy (PRRT), have been explored. In the case of ¹⁷⁷Lu-EDTMP, the whole-body images obtained are compared with those recorded using ^99mTc-MDP in the same patient. On the other hand, pre-therapy images acquired with ¹⁷⁷Lu-DOTA-TATE are compared with similar images obtained with standard agents, such as ^99mTc-HYNIC-TOC (SPECT) and ⁶⁸Ga-DOTA-TOC (PET) in the same patient. The advantage of the long physical half-life (T_1/2) of ¹⁷⁷Lu has been utilized in mapping the pharmacokinetics of two additional agents, ¹⁷⁷Lu-labeled hydroxyapatite (HA) in radiation synovectomy of knee joints and ¹⁷⁷Lu-HA for therapy of hepatocellular carcinoma. Results of these multiple studies conclusively document the potential of ¹⁷⁷Lu as a theranostic radioisotope

Cite this article as:

Das Tapas and Banerjee Sharmila, Theranostic Applications of Lutetium-177 in Radionuclide Therapy, Current Radiopharmaceuticals 2016; 9 (1) . https://dx.doi.org/10.2174/1874471008666150313114644